# An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

> **NCT03446274** · PHASE1 · UNKNOWN · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 6 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Evenamide

## Key facts

- **NCT ID:** NCT03446274
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-02
- **Primary completion:** 2018-04-23
- **Final completion:** 2018-06
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446274, "An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03446274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*